A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma
Regeneron Pharmaceuticals
560 participants
Sep 9, 2024
INTERVENTIONAL
Conditions
Summary
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)
Eligibility
Inclusion Criteria6
- Participants with histologically confirmed unresectable stage III and stage IV (metastatic) melanoma per American Joint Committee on Cancer (AJCC), eighth revised edition.
- Participants must not have received prior systemic therapy for unresectable or metastatic melanoma as described in the protocol.
- Measurable disease per RECIST version 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1
- Adequate bone marrow, hepatic, and kidney function
- Known B-Rapidly Accelerated Fibrosarcoma protein (BRAF) V600 mutation status or submitted sample for BRAF V600 mutation assessment as described in the protocol
Exclusion Criteria11
- Medical Conditions:
- Uveal, acral or mucosal melanoma.
- Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents as described in the protocol.
- Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C virus (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection. Mild cancer-related immunodeficiency (such as immunodeficiency treated with gamma globulin and without chronic or recurrent infection) is allowed.
- Prior/Concomitant Therapy:
- Prior immune checkpoint inhibitor therapy other than anti-PD1/PD-L1 as described in the protocol
- Systemic immune suppression as described in the protocol.
- Other Comorbidities:
- Participants with a history of myocarditis.
- Troponin T (TnT) or troponin I (TnI) \>2x institutional upper limit of normal (ULN).
- Active or untreated brain metastases or spinal cord compression as described in the protocol.
Interventions
Intravenous (IV) administration every 3 weeks (Q3W) in combination with cemiplimab
IV administration Q3W in combination with fianlimab
IV administration every 4 weeks (Q4W)
Locations(108)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06246916